By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


MabVax Therapeutics, Inc. 

11588 Sorrento Valley Road
Suite 20
San Diego  California  92121  U.S.A
Phone: 858-259-9405 Fax:



Company News
MabVax Therapeutics Announces FDA Authorization To Proceed With MVT-1075 In A Phase I Clinical Trial For The Treatment Of Pancreatic Cancer 2/23/2017 6:50:33 AM
MabVax Therapeutics Studies Lead Investigational Drug MVT-5873 With Halozyme (HALO) PEGPH20 2/13/2017 6:48:33 AM
MabVax Therapeutics Files Investigational New Drug Application For Novel Radioimmunotherapy Agent MVT-1075 1/9/2017 7:48:01 AM
MabVax Therapeutics Expands Phase I Clinical Trial Investigation For Patients With Pancreatic Cancer To Include Honorhealth Research Institute 12/5/2016 8:30:42 AM
MabVax Therapeutics Enrolls First Patients In Expansion Of Phase I Clinical Trial Treating Newly Diagnosed Pancreatic Cancer Patients 11/28/2016 6:23:37 AM
MabVax Therapeutics To Hold Conference Call To Provide Corporate Update On Monday, November 14, 2016 11/15/2016 8:44:58 AM
MabVax Therapeutics Reports Interim Safety And Imaging Results From Phase I Clinical Trials In Humab-5B1 Antibody Development Programs 11/14/2016 7:36:18 AM
MabVax Therapeutics Reports Third Quarter 2016 Financial Results And Schedules Conference Call To Provide Corporate Update On Monday, November 14, 2016 11/11/2016 2:03:19 PM
MabVax Therapeutics Receives U.S. Patent For Its Clinical Stage HuMab-5B1 Antibody 11/7/2016 12:42:03 PM
MabVax Therapeutics Humab-5B1 Based Diagnostic Imaging And Radioimmunotherapy Programs Featured At The 2016 World Molecular Imaging Congress 9/26/2016 10:13:40 AM